#United States #Rancho Cucamonga #BAQSIMI #Primatene MIST #Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Reports Strong Financial Results for Q3 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) has recently unveiled noteworthy financial outcomes for the third quarter ending September 30, 2026. With a net revenue reaching $207.6 million, the company marked an 8% increase compared to the same quarter of the previous year, which reflects its continued growth trajectory and effective market strategies.

Financial Highlights

In the report, Amphastar recorded a GAAP net income of $37.8 million, translating to $0.87 per share, showcasing a significant improvement from the previous year's $17.35 million net income. Adjusted non-GAAP net income also exhibited a strong performance, amounting to $49.3 million or $1.14 per share. This growth is attributed to the robust sales performance of key products and a strategic focus on enhancing their diverse portfolio.

Dr. Jack Zhang, the President and CEO of Amphastar, noted, "Our results from the third quarter reflect the strengths of our diversified offerings and the commercial framework we have built. The record sales of BAQSIMI and Primatene MIST, along with other new product contributions, have been instrumental in this growth. We are committed to advancing our ongoing programs in complex generics, biosimilars, and proprietary pharmaceuticals while also boosting our manufacturing and development capabilities to sustain long-term growth."

Breakdown of Sales Growth

The standout products during this quarter included:

• - BAQSIMI®: Sales rose to $58.8 million, a 10% increase, supported by augmented unit volumes from marketing initiatives, although offset somewhat by lower average selling prices due to pricing strategies and customer mix variations.
• - Primatene MIST®: Sales also grew, landing at $31.5 million, benefiting from both a price increase and heightened unit demand.
• - Lidocaine: This product experienced a notable escalation in sales by 29% due to increased demand from supplier shortages.

In contrast, there was a reported decline in sales for Epinephrine and Glucagon, primarily due to reduced unit volumes and heightened market competition.

Cost Management and Future Ready

Total costs rose by 16% to $107.9 million, primarily driven by manufacturing expenses linked to ongoing remediation efforts and facility expansion needs. However, gross profits stood at $99.6 million, representing a gross margin of 48%, slightly down from the previous year, but indicative of a healthy profit despite rising costs.

Amphastar’s operational expenses also saw fluctuations; selling and marketing expenses rounded off to $11.9 million due to higher freight costs, while general administrative expenses significantly decreased due to a remarkable reduction in previous legal provisions.

Strategic Developments

In light of these strong results, Amphastar’s Board of Directors also announced a $50 million increase in its share buyback program aimed at mitigating dilution from equity compensation. The program allows repurchases through various avenues, including open-market purchases, demonstrating the company's commitment to returning value to shareholders while maintaining flexibility in capital allocation.

Currently, Amphastar is pursuing multiple projects within its development pipeline, including an abbreviated new drug application (ANDA) and biosimilars targeting a combined market exceeding $1.6 billion. These efforts reflect the company’s strategy to capture substantial market segments while addressing healthcare needs effectively.

Dr. Zhang emphasized their ongoing commitment to executing their strategy meticulously and fostering growth that ultimately benefits their shareholders and the communities they serve. The company’s confidence in its capabilities and products positions it favorably as they head towards future product launches and potential market expansions.

To further discuss the quarter's results, Amphastar will host a conference call today, providing investors and analysts a platform for in-depth dialogues regarding their performance and future endeavors.

Conclusion

In summary, Amphastar Pharmaceuticals continues to exhibit growth and resilience in the biopharmaceutical landscape. With focused strategies in product development and management, the company is well-positioned for sustained long-term success in the industry.